Product Description
Novartis is developing mak-683, an Oral EED Inhibitor for Diffuse Large B-cell Lymphoma. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02900651)
Mechanisms of Action: EED Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Novartis
Company Location: Europe
Company Founding Year: 1996
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Japan
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Lymphoma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
JapicCTI-173493 |
JapicCTI-173493 | P2 |
Active |
Lymphoma |
None |